W
hereas human clinical gene therapy trials for cancer have not yielded clear benefit to date, these studies have served to highlight the deficiencies of current approaches. In this regard, a number of cancer gene therapy approaches have been developed based on direct correction of cancer-relevant genetic lesions. These "mutation compensation" approaches represent a diversity of specific interventions, all designed to rectify the molecular lesions etiologic of neoplastic transformation/progression, and have demonstrated efficacy in numerous reports in the context of in vitro and in vivo model systems. Application of these approaches for human disease requires direct, in situ delivery of these anticancer genes. Furthermore, this must be achieved in the context of a plurality of the neoplastic cells. This requirement predicates the need for gene delivery vectors capable of efficient and selective gene delivery to tumor cells in the context of in vivo gene delivery schemas. In this regard, one of the major findings of human clinical gene therapy trials for cancer has been a disappointingly low level of achieved gene transfer. Thus, despite demonstrated efficacy in model systems, the primary tumor has proved to be relatively refractory to the same vector systems. These results have provoked an analysis of this phenomenon whereby, in some instances, the basis of tumor cell resistance can be defined. For instance, one of the major vector systems employed for cancer gene therapy is the recombinant adenovirus (Ad). 3 Analysis of a variety of primary tumors has demonstrated profound deficiencies in the primary receptor for Ad, Coxsackie and Ad receptor (CAR), which serves to explain the observed tumor cell vector resistance in human clinical trials.
Gene delivery
The recognition that CAR deficiency is a nearly universal feature of epithelial neoplasms has predicated the need for adenoviral vectors capable of "CAR-independent" gene delivery. 4 Strategies that have been endeavored to achieve this employ retargeting complexes as well as genetic capsid modifications. The ability to achieve CAR-independent gene delivery has allowed effective infection of otherwise refractory tumor cells. This has allowed direct therapeutic gain in the context of murine models of human neoplastic disease. These new vector paradigms are being evaluated currently in the context of tumor clinical trials. Of note, it was the earlier generation of human clinical trials that first revealed the biological limits of current generation vectors. On this basis, vector design modifications were endeavored that allowed vector improvement with a direct gain in model systems of cancer. 4 Clearly, future human clinical trials with the advanced-generation vectors will provide the ultimate test of efficacy. In any event, the role of direct clinical translation in allowing rational advancement of cancer gene therapies is clearly illustrated.
Replicative vectors
The recognition that advanced-generation vectors are limited in their in vivo transduction efficacy has also led to the development of novel anticancer gene therapies embodying the principles of posttransductional amplification. In this scheme, an initial transduction event provokes a biological cascade whereby anticancer effects, over and above the transduced cells, are achieved. One such approach employs replicating viral agents. A variety of viruses have been employed to this end, including parvovirus, 5 herpes viruses, 6 reovirus, 7 and Ad. 3 The unifying feature of these agents is that the antitumoral effect is achieved directly by virtue of the replicative cycle of the virus. Such antitumoral "oncolysis" is ideally achieved in a fashion whereby the virus replicates selectively in tumor cells. A conceptually attractive aspect of these systems is their intrinsic ability to achieve an amplified effect via the capacity of infectious viruses to lateralize within the context of solid tumors. On this basis, replicative viral agents have been recognized as agents of exceptional promise and have been rapidly translated into human clinical gene therapy trials. As noted previously in the context of the issue of vector efficacy, clinical trials carried out to date with replicative viral agents have revealed limitations in these systems that were not fully noted in model systems. In the first instance, tumor cell resistance to viral infection based on viral receptor deficiency presents a barrier to viral lateralization. Thus, vector modifications will be required to address this limit of effective amplification. In addition, the achievement of precise replicative specificity has been more difficult to achieve than initially envisioned. It must therefore be recognized that the rapid translation of these agents into clinical trials will mainly serve to highlight key functional areas warranting address. For advanced-generation vectors, it may be anticipated that such design reconfigurations will yield a direct gain in terms of therapeutic results.
Prodrug therapy
Another approach to overcome the limited transduction efficiency of the currently available vectors is the use of enzyme-prodrug systems, with herpes simplex thymidine kinase gene/ganciclovir as the best known example of this approach. 8 For this purpose, vectors containing a gene for a foreign enzyme have been constructed. Once expression of the enzyme in a limited number of tumor cells has occurred, a nontoxic prodrug is administered that, in the close surroundings of the enzyme-producing tumor cells, is converted into a toxic drug. The expression of the enzyme in the target cells can be achieved either by using targeted vectors, for instance by coupling to a single-chain Fv antibody, 9 or by using tissue-specific promoter systems. 10 Although many promising preclinical results have been achieved, confirming the proof of principle, the induction of clinical responses in humans still has to be confirmed.
Immunotherapy
So far however, most cancer gene therapy trials involve immunotherapeutic approaches. Based on the increasing knowledge regarding tumor-associated antigens (Ags) and Ag presentation, new approaches for gene immunotherapy are being designed. Research on dendritic cells is aimed at specific transduction of these Ag-presenting cells with integrins or CD40 as target Ags, to further improve the functioning of these cells. The first clinical results with cDNA vaccination against carcinoembryonic Ag, with dendritic cells loaded with mRNA or with tumor cells transduced with the granulocyte-macrophage colony-stimulating factor gene, demonstrated limited clinical benefit in patients with endstage disease. In a melanoma trial with autologous, irradiated tumor cells transduced with granulocyte-macrophage colony-stimulating factor, 20% of patients who received three vaccinations were still alive after a follow-up of 3-5 years.
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Clinical trial design In the paradigms presented, information gained in human clinical trials has allowed rational steps to improve the design of gene-based anticancer agents. Whereas this recognition argues for stringent clinical evaluation of new agents, it also mandates that maximal information be derived from these trials. Heretofore, the realization of such key information has not been fully feasible based on the crude and invasive methods of gene transfer/expression employed. A number of groups have recently developed noninvasive imaging methods as a means to monitor heterologous vector-mediated gene expression. 12 These systems offer a number of advantages for this type of analysis and potentially provide a truly dynamic method to achieve the key goal of interval data, short of direct therapeutic benefit. The evaluation of these systems in human trials remains to be endeavored. Nonetheless, such systems may prove pivotal in guiding the empiric development of future generations of anticancer agents.
CONCLUSIONS
Overall, the central lessons of the conference were clear: (a) human clinical studies provide the ultimate test to defining limits of current strategies; (b) information from these trials can guide the rational address of current system limits; and (c) derived advancedgeneration systems can provide truly impressive gains in the therapeutic potential achieved. It is hoped that these central lessons represent a pivotal paradigm for future endeavors in this field so that true "therapeutic" results can be reported in cancer gene therapy, and that cancer gene therapy will join the ranks of gene therapy successes.
